News Sentiment

AGMB sentiment intelligence

AgomAb Therapeutics NV American Depositary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 12.04 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-8.0% over one week, +9.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Enterprise value to EBIT forward of AgomAb Therapeutics NV – NASDAQ:AGMB

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -8.0% Price reacting lower
Trend fit Trend inactive 9.7% over four weeks
Fair value -1.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 28
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 8
TradingView 6
Finviz 3
MT Newswires 2
Investing.com Nigeria 2
Seeking Alpha 2
The Manila Times 2

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 17
Analyst action 3
Regulatory and legal 3
Deals and strategy 3
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-47 of 47
TradingView Direct company coverage

Number of shareholders of AgomAb Therapeutics NV – NASDAQ:AGMB

This page from TradingView provides information about AgomAb Therapeutics NV (NASDAQ:AGMB), specifically focusing on the number of shareholders. It indicates that the market for AGMB is currently closed, and presents a section for charting the period, value, and percentage change

Tone
Neutral 50/100
Event
Market update
Published
09 May 2026 06:40
Source
TradingView
The Globe and Mail Direct company coverage

Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones

Agomab Therapeutics NV ADR (AGMB) reported a €62.5 million net loss in 2025 but significantly strengthened its cash reserves to €116.5 million, further bolstered by $208 million from its February 2026 IPO, extending its cash runway into mid-2029. The biopharma company plans to in

Tone
Positive 67/100
Event
Balance sheet
Published
26 Apr 2026 06:40
Source
The Globe and Mail
Stock Titan Direct company coverage

IPO cash extends Agomab (Nasdaq: AGMB) runway and backs 2026 trials

Agomab Therapeutics (AGMB) reported full-year 2025 results, showing a net loss of €62.5 million but a significantly strengthened balance sheet after raising $208 million gross proceeds from its February 2026 IPO. This funding is expected to extend the company's cash runway into t

Tone
Positive 66/100
Event
Earnings
Published
24 Apr 2026 20:40
Source
Stock Titan
The Manila Times Direct company coverage

Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

Agomab Therapeutics NV reported its full-year 2025 financial results, highlighting significant clinical progress and strong financial positioning. The company secured €116.5 million in cash and cash investments by December 31, 2025, and an additional $208 million from its IPO in

Tone
Positive 72/100
Event
Earnings
Published
23 Apr 2026 22:38
Source
The Manila Times
Stock Titan Direct company coverage

After a $208M IPO, Agomab says cash lasts into 2029

Agomab Therapeutics (NASDAQ: AGMB) reported its full-year 2025 financial results and reconfirmed its 2026 outlook. The company's cash and short-term investments of €116.5 million as of December 31, 2025, combined with $208 million gross IPO proceeds in February 2026, are expected

Tone
Positive 64/100
Event
Earnings
Published
23 Apr 2026 22:38
Source
Stock Titan
Quiver Quantitative Direct company coverage

Agomab Therapeutics Reports Strong Financial Position and Clinical Advancements Ahead of Phase 2 Trials in Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis

Agomab Therapeutics announced strong financial results for 2025, with €116.5 million in cash and cash investments and $208 million raised from its IPO, extending its cash runway into the first half of 2029. The company made significant clinical progress, including positive FDA in

Tone
Positive 66/100
Event
Earnings
Published
23 Apr 2026 22:20
Source
Quiver Quantitative
Market source Direct company coverage

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

AgomAb Therapeutics NV (NASDAQ:AGMB) secured a U.S. patent for its investigational drug AGMB-447, an ALK5 inhibitor for idiopathic pulmonary fibrosis, providing protection through at least 2041. This news follows optimistic analyst coverage from Leerink and JPMorgan, who issued O

Tone
Positive 74/100
Event
Regulatory and legal
Published
12 Apr 2026 23:08
Source
Market source